Results 31 to 40 of about 422,103 (237)

Clinical Update of Severe Fever with Thrombocytopenia Syndrome

Viruses, 2021
Severe fever with thrombocytopenia syndrome (SFTS) is an acute febrile illness characterized by fever, leukopenia, thrombocytopenia, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting resulting from infection with the SFTS virus (SFTSV).
Jun-Won Seo, Da-Young Kim, N. Yun, Dong-Min Kim   +3 more
semanticscholar   +1 more source

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [PDF]

, 2014
PurposeWe hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway.
Amin, Hesham M, Angelo, Laura S, Falchook, Gerald S, Hess, Kenneth, Hong, David, Howard, Adrienne N, Huang, Mei, Jackson, Edward F, Janku, Filip, Kurzrock, Razelle, Lawhorn, Kristie N, Naing, Aung, Ng, Chaan S, Parkhurst, Kristin L, Tannir, Nizar M, Vishwamitra, Deeksha, Wheler, Jennifer J   +16 more
core   +13 more sources

A Retrospective Observational Single-Centre Study on the Burden of Immune Thrombocytopenia (ITP) [PDF]

, 2012
Background: German data on economic consequences of immune thrombocytopenia (ITP) are limited. Patients and Methods: A retrospective, observational study based on chart review of adult patients with a confirmed diagnosis of ITP was conducted at a German ...
Ackermann, Birgit, Bauer, Matthäus, Baumann, Anja, Berger, Karin, Ostermann, Helmut, Schopohl, Dorothee, Shlaen, Rita   +6 more
core   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Blood Advances, 2019
BACKGROUND Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. OBJECTIVE These evidence-based
C. Neunert, Deirdra R. Terrell, D. Arnold, G. Buchanan, D. Cines, N. Cooper, A. Cuker, J. Despotovic, J. George, R. Grace, T. Kühne, D. Kuter, W. Lim, K. McCrae, Barbara Pruitt, Hayley Shimanek, S. Vesely   +16 more
semanticscholar   +1 more source

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken, Arnoud W. J. van 't Hof, Jurriën M. ten Berg, Dean J. Kereiakes, Barry S. Coller   +4 more
doaj   +1 more source

A Novel DNA Repair Disorder With Thrombocytopenia, Nephrosis, and Features Overlapping Cockayne Syndrome [PDF]

, 2009
We report on four siblings with Cockayne-like syndrome with thrombocytopenia and nephrotic syndrome. The parents were healthy and consanguineous, consistent with an autosomal recessive mode of disease inheritance.
Cockayne, Funaki, Hirooka, Kruglyak, Lehmann, Lehmann, Mallery, Mayne, Nance, Reiss, Sato, Tan   +11 more
core   +3 more sources

Pattern Analysis of Thrombocytopenia in Dengue versus Non-Dengue Patients [PDF]

National Journal of Laboratory Medicine, 2018
Introduction: Dengue fever is one of the most prevalent and fastest spreading mosquito-borne arboviral infection occurring in tropical and sub-tropical regions around the world and leads to explosive outbreaks in urban areas influenced strongly by ...
Smitha Bhaskar, Sandhya Ilanthodi, Purnima S Rao, Prithal Gangadhar, Parineetha V Shetty, Deepak Panasseril, Manjula Anil   +6 more
doaj   +1 more source

Discussion required for correct interpretation [PDF]

, 2006
Thank you for the opportunity to comment on the editorial by Romero and colleagues [1], which raises a number of important and interesting questions.
Aguan, Bethin, Challis, Chan, Gary D. V Hankins, George R Saade, Radek Bukowski, Romero, Slater, Sparey, Steve Thornton   +10 more
core   +3 more sources

Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources

Journal of Thrombosis and Haemostasis, 2021
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immunological reaction to the non‐replicable adenoviral vector‐based COVID‐19 vaccines.
A. Greinacher, F. Langer, M. Makris, M. Pai, S. Pavord, H. Tran, T. Warkentin   +6 more
semanticscholar   +1 more source